Substantial research is focused on understanding the pivotal role of neuroinflammation in disease progression, with evidence linking both innate and adaptive immune processes to the pathogenesis of AD ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, ...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, ...

GLP-1 receptor agonists may confer neuroprotection via reduced neuroinflammation, inhibited apoptosis, and vasodilatory effects that enhance cerebral perfusion through cAMP and VEGF-related pathways.

For adults with obesity but without diabetes, GLP-1 RA use is associated with a significantly lower short-term incidence of OACs.

More than half of adults with T2DM who discontinue glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reinitiate within ...

When obesity and psoriatic diseases were treated concomitantly with a biologic and a GLP-1 receptor agonist (RA), more than 90% of patients reported satisfaction with their treatment, in a newly ...

A review suggests GLP-1 receptor agonists may help reduce inflammation in psoriasis, atopic dermatitis, and other skin ...

A novel unimolecular GLP-1/amylin receptor agonist conferred reductions in HbA1c and body weight for adults with type 2 ...

Aim To review the impact of glucagon-like peptide-1 (GLP-1) receptor agonists on the facial profile and oral cavity and to highlight their relevance to dental practice. Methods A narrative review of ...

A total of 10,225 patients with stage I to III cancer who initiated GLP-1 RA therapy after diagnosis were identified for the trial. HealthDay News — Across multiple solid tumors, glucagon-like peptide ...